Conference Reports for NATAP

Back

HEPDART 2013: Frontiers in Drug Development for Viral Hepatitis December 8-12, 2013 Big Island, Hawaii     HepDART December 2013 Selected Slide Presentations (01/24/14)   Efficient Hepatic Delivery of Tenofovir by Prodrug Tenofovir Alafenamide in Nonclinical Studies Supports Low-Dose Treatment of Hepatitis B Virus (12/20/13)   High Sustained Virologic Response Rates With Sofosbuvir Regimens Irrespective of Ribavirin Dose Reductions (12/20/13)   In Vitro Activation of Sofosbuvir in Primary Human Hepatocytes (12/20/13)   High Sustained Virologic Response Rates With Sofosbuvir Regimens Irrespective of Ribavirin Dose Reductions - Slide Talk (12/18/13)   A Fixed-Dose Combination of Sofosbuvir and Ledipasvir Is Highly Effective in Treatment-Naïve and Treatment-Experienced Genotype 1 HCV-Infected Patients: Results from the LONESTAR and ELECTRON Phase 2 Studies (12/18/13)   A Fixed-Dose Combination of Sofosbuvir and Ledipasvir Is Highly Effective in Treatment-Naïve and Treatment-Experienced Genotype 1 HCV-Infected Patients: Results From the LONESTAR and ELECTRON Phase 2 Studies - poster (12/18/13)   Daclatasvir: Present and Future DAA Combinations (12/18/13)   Simeprevir Overview: From IFN-Containing to IFN-Free Regimens (12/18/13)   NS3/4A BASELINE POLYMORPHISMS AND TREATMENT-EMERGENT VARIANTS IN HCV GENOTYPE-1-INFECTED, TREATMENT-NAIVE PATIENTS FROM THE PHASE III STARTVerso 1 AND 2 CLINICAL STUDIES OF FALDAPREVIR PLUS PEGYLATED INTERFERON α-2A AND RIBAVIRIN (12/16/13)   TD-6450, a Heterodimeric HCV NS5A Inhibitor with a High Barrier to Resistance and Pan-Genotypic Potency (12/16/13)   Impact of Chronic Hepatitis C (CHC) Treatment on Post Therapy Healthcare Cost: HCV Therapy Completers Had Significantly Reduced Post Therapy Healthcare Costs (12/16/13)   No Pharmacokinetic Interaction Between the Hepatitis C Virus Non-Structural Protein 5A Inhibitor MK-8742 and Ethinyl Estradiol and Levonorgestrel (12/16/13)   No Meaningful Pharmacokinetic Interaction Between Hepatitis C Virus Protease Inhibitor MK-5172 and Ethinyl Estradiol and Levonorgestrel (12/16/13)   Lack of PK Interaction Between the Hepatitis C Virus Non-Structural Protein 5A Inhibitor MK-8742 and Methadone in Subjects on Stable Opiate Maintenance Therapy (12/16/13)   Pharmacokinetic Interaction Of HCV Protease Inhibitor MK-5172 and Ritonavir in Healthy Subjects (12/16/13)